SAN DIEGO and TORONTO, March 06, 2018 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the upcoming conferences:
- Cowen and Company 38th Annual Healthcare Conference
| Time: | 12:00 p.m. EDT | ||
| Date: | Monday, March 12, 2018 | ||
| Location: | The Boston Marriott Copley Place, Boston, MA | ||
| Live webcast: | http://wsw.com/webcast/cowen46/apto/ | ||
- 30th Annual ROTH Conference
| Time: | 9:30 a.m. PDT | ||
| Date: | Tuesday, March 13, 2018 | ||
| Location: | The Ritz Carlton, Laguna Niguel, CA | ||
| Live webcast: | http://wsw.com/webcast/roth32/apto/ | ||
- 2018 B. Riley & Co. China Healthcare Investment Partnering Symposium
| Time: | 11:30 a.m. CST (China Standard Time) | ||
| Date: | Friday, March 16, 2018 | ||
| Location: | The Intercontinental Hotel, Hangzhou, People’s Republic of China | ||
| Live webcast: | http://wsw.com/webcast/brileyco20/apto/ | ||
- Oppenheimer 28th Annual Healthcare Conference
| Time: | 8:00 a.m. EDT | ||
| Date: | Wednesday, March 21, 2018 | ||
| Location: | The Westin Grand Central, New York, NY | ||
| Live webcast: | https://veracast.com/webcasts/opco/healthcare2018/76201109497.cfm | ||
The audio webcasts can also be accessed through the Aptose website at www.aptose.com and will be archived shortly after the live event and available for 90 days.
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com.
For further information, please contact:
Aptose Biosciences
Greg Chow, CFO
647-479-9828
Email: [email protected]
| SMP Communications Susan Pietropaolo 201-923-2049 [email protected] | LifeSci Advisors Michael Wood Managing Director 646-597-6983 [email protected] |


Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
DeepSeek to Raise AI API Prices as Demand for New Models Surges
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales
OpenAI Restricts Astra AI Over Cyberattack Risks
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 



